VP, a selective YAP inhibitor, has been reported to exert therapeutic effects in inflammatory skin disorders, while also attenuating fibrosis and promoting scar-free skin regeneration through inhibition of TGFβ-induced actin stress fiber formation in dermal fibroblasts (126). This evidence concerns the gene YAP1 and inflammatory skin disease.